All In MedTech

Device Trial Radar · NCT05099874

Feasibility and Efficacy of Attentional-Control Training in Sickle Cell Disease

Last checked: Nov 19, 2026Latest source record: Jan 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Dec 20, 2022

Primary completion

Dec 2025

Study completion Dec 2025

Sponsor

Lead sponsor
Children's National Research InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 29, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 8 years, up to 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Children with sickle cell disease (SCD) exhibit significantly reduced cognitive functioning (often difficulties with attention) compared to peers and siblings without SCD. EndeavorRx (Akili Interactive Labs: Boston, MA) is an FDA-approved home-based, electronic attentional-control training program designed to treat attention problems in youth. Users access EndeavorRx on a tablet device for 25-30 minutes each day, 5 days per week, for 4 weeks. The program involves training in a game-like environment that repeatedly challenges attentional-control abilities and adapts to user performance, becoming more difficult over time as performance improves. This pilot study is examining the feasibility, acceptability, and preliminary efficacy of EndeavorRx in a sample of 20 children with SCD ages 8-16 who are being treated with chronic blood transfusion therapy.

Conditions

  • Sickle Cell Disease
  • Attention Deficit
  • Cognitive Deficit in Attention

Interventions

  • EndeavorRxDevice

    EndeavorRx is a digital intervention delivered through an action video game that is indicated to improve attention function. EndeavorRx users first complete two discrete tasks: 1) a perceptual discrimination/attention task in which users respond to target stimuli and ignore distractor stimuli (e.g., tapping the screen quickly only when red aliens appear) and 2) a sensorimotor navigation task in which users tilt their device to steer a hovercraft down a river while targeting or avoiding certain objects. Users are subsequently presented with a multitask training session where they complete the perceptual discrimination/attention task and the sensorimotor navigation task simultaneously. Algorithms adapt the program in both real-time and between sessions to automatically adjust the difficulty level.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. EndeavorRx feasibility assessed by patient/family interestTime frame: Approximately 10 months
  2. EndeavorRx feasibility assessed by program completion ratesTime frame: Approximately 4 weeks per participant
  3. EndeavorRx feasibility assessed by reports of technical ease-of-use and satisfactionTime frame: Approximately 4 weeks from start of intervention

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Children's National Hospital

    Washington D.C., District of Columbia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.